Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.65 |
| ▸ | CA2 | P00918 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24278251 | 1.00 | CA1 (0.65) | CA1CA2ALDH1A1LMNACTSK | |
| SCHEMBL24692539 | 0.96 | CA1 (0.60) | CA1CA2ALDH1A1LMNACTSK | |
| SCHEMBL26814988 | 0.92 | HSD11B1 (0.56) | CA1CA2ALDH1A1LMNACTSK | |
| SCHEMBL25819298 | 0.90 | CA1 (0.62) | CA1CA2CTSKHSD11B1CYP2C9 | |
| SCHEMBL28619437 | 0.87 | CA1 (0.65) | CA1CA2CTSKHSD11B1CYP2C9 | |
| SCHEMBL28634903 | 0.86 | CA1 (0.49) | CA1CA2CTSKHSD11B1CYP2C9 | |
| SCHEMBL21423818 | 0.85 | CA1 (0.62) | CA1CA2ALDH1A1CTSKHSD11B1 | |
| SCHEMBL21423826 | 0.85 | CA1 (0.62) | CA1CA2ALDH1A1CTSKHSD11B1 | |
| SCHEMBL19409031 | 0.85 | CA1 (0.62) | CA1CA2CTSKHSD11B1CYP2C9 | |
| SCHEMBL23196344 | 0.84 | CA1 (0.61) | CA1CA2ALDH1A1CTSKHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| EP-4157849-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2023-04-05 | — | — | EP | disclosed |
| WO-2023017442-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018238-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CA1 4096/4885CA2 4604/4885ALDH1A1 4008/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | CA1 3790/4885CA2 4449/4885ALDH1A1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.